- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
PMCPA found Novo Nordisk breached Clauses 2, 5.1/9.1 and 28.1 over pharmacy-chain sponsorships that weren’t truly arm’s length, free consumables seen as…
Complaint said a Rinvoq HCP webinar registration page gave dosing but omitted the SmPC grapefruit avoidance warning. Panel found the page wasn’t…
Complaint about a regional e-consent proposal and alleged proactive sharing of preprint data/off-label risk. Panel found the complainant provided limited evidence and…
Anonymous complaint alleged inadequate whistleblowing processes and potential off-label promotion via a Moderna US webcast. Panel found the complainant did not prove…
A Sanofi Global employee’s LinkedIn job update included three product brand names and was liked/commented on by UK staff. Panel found the…
A US-only Apretude in-app advert was briefly visible to UK users after geo-restrictions failed. Panel initially found a Clause 5.1 breach, but…
Third‑party publisher email implied an unbiased ESMO update but linked to a page integrating Novartis Pluvicto promotion. UK HCPs saw EU SmPC/indication,…
Ex-employee alleged excessive alcohol/hospitality and inducement to prescribe at a conference, plus a poorly attended workshop becoming a “pseudo advisory board”. Panel…
Ex-employee complaint about Ontozry meetings. Panel found off-label promotion (incl PEG administration and monotherapy advocacy), references to EMA, and multiple certification/PI/AE statement…
Competitors alleged an Actonel exhibition panel used out-of-licence safety data and downplayed SPC GI warnings. The Panel found the panel clearly related…
Baxter alleged Johnson & Johnson used the Trasylol (aprotinin) safety alert to promote Quixil in a misleading way. The Panel found briefing…
A leavepiece for Acomplia was ruled misleading for implying broader NICE approval than guidance allowed, altering the emphasis of NICE wording on…
GSK challenged Pfizer’s Champix detail aid claims on quit rates, NNT, cost-effectiveness and safety information. The Panel found the data were presented…
A pharmacist challenged comparative efficacy and tolerability claims for Versatis versus pregabalin/gabapentin. The Panel found interim data and SPC references did not…
Cephalon challenged ProStrakan’s claim that Abstral provided rapid relief from 10 minutes. The Panel found the claim inconsistent with the Abstral SPC,…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.